NH-Amundi Asset Management Lists HANARO Bio Korea Active ETF

NH-Amundi Asset Management announced on the 26th that it will list the HANARO Bio Korea Active ETF.

The HANARO Bio Korea Active ETF is a product that focuses on investing in domestic bio healthcare companies. It pursues excess returns compared to the benchmark index through active management.

The benchmark index is the iSelect K-Bio Healthcare Index. The constituent stocks of the benchmark index include Samsung Biologics, Celltrion, Alteogen, and other domestic companies with global competitiveness in various fields such as CDMO, biosimilars, biotech, and comprehensive pharmaceutical companies.

NH-Amundi Asset Management explained that now, as the domestic bio healthcare industry is entering a rising phase, is the right time to invest in this industry.

The main factors that led the stock price rise of domestic bio healthcare companies in the second half of this year are still valid. It is expected that profit inflows from new drug development will be in full swing starting from the second half of next year.

Hyunbin Kim, Head of ETF Investment at NH-Amundi Asset Management, introduced, "The HANARO Bio Korea Active ETF is an effective product for investing in the high growth potential of domestic K-Bio."

This content was produced with the assistance of AI translation services.